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Objectives This study sought to determine the association of fibroblast growth factor (FGF)-23 with death, heart failure (HF), and cardio-
vascular disease (CVD) in the general population, as well as the influence of chronic kidney disease (CKD) in this setting.
Background FGF-23 increases renal phosphorus excretion and inhibits vitamin D activation. In end-stage renal disease, high
FGF-23 levels are associated with mortality. The association of FGF-23 with death, HF, and CVD in the general
population, and the influence of CKD in this setting, are unknown.
Methods Plasma FGF-23 was measured in 3,107 community-living persons 65 years of age in 1996 and 1997, and par-
ticipants were followed through 2008. HF and CVD events were adjudicated by a panel of experts. Associations
of FGF-23 with each outcome were evaluated using Cox proportional hazards models, and we tested whether
associations differed by CKD status.
Results Both lower estimated glomerular filtration rate and higher urine albumin to creatinine ratios were associated with
high FGF-23 at baseline. During 10.5 years (median) follow-up, there were 1,730 deaths, 697 incident HF events, and
797 incident CVD events. Although high FGF-23 concentrations were associated with each outcome in combined
analyses, the associations were consistently stronger for those with CKD (p interactions all 0.006). In the CKD group
(n  1,128), the highest FGF-23 quartile had adjusted hazards ratios (HR) of 1.87 (95% confidence interval [CI]: 1.47
to 2.38) for all-cause death, 1.94 (95% CI: 1.32 to 2.83) for incident HF, and 1.49 (95% CI: 1.02 to 2.18) for incident
CVD events compared with the lowest quartile. Corresponding HRs in those without CKD (n  1,979) were 1.29
(95% CI: 1.05 to 1.59), 1.37 (95% CI: 0.99 to 1.89), and 1.07 (95% CI: 0.79 to 1.45).
Conclusions FGF-23, a hormone involved in phosphorous and vitamin D homeostasis, is independently associated with all-
cause death and incident HF in community-living older persons. These associations appear stronger in persons
with CKD. (J Am Coll Cardiol 2012;60:200–7) © 2012 by the American College of Cardiology Foundation
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July 17, 2012:200–7 FGF23 and CVD Events in the CommunityFibroblast growth factor (FGF)-23 is a 32KDa hormone se-
creted into blood from bone osteocytes. Its 2 functions are to
induce urinary phosphorus excretion and to inhibit activation
of vitamin D; both actions occur in the renal proximal tubule.
Rare human disorders of FGF-23 excess are characterized by
high renal phosphorus excretion, low serum phosphorus levels,
calcitriol deficiency, osteomalacia, and spontaneous fractures
(1). Recent in vitro and rodent studies also suggest that FGF-23
ay directly influence cardiac myocytes to hypertrophy (2).
Circulating FGF-23 concentrations are often several
rders of magnitude higher in patients with end-stage renal
isease and are strongly associated with mortality risk in that
etting (3). The association of FGF-23 with mortality was
ecently extended to individuals with moderate to severe
hronic kidney disease (CKD), and to populations with
nown prevalent cardiovascular disease (CVD) (4–7). Little
s known about FGF-23 levels in community-living indi-
iduals without CKD or CVD (8).
The purpose of this study was to examine the relationship
f FGF-23 with all-cause death, incident heart failure (HF),
nd incident CVD events in a free-living population of
lder persons with long-term follow-up, and considerable
umbers of events. We aimed to determine the strength of
he association of FGF-23 with kidney function at the
aseline visit and to examine the extent to which associa-
ions of FGF-23 with longitudinal outcomes were depen-
ent on presence of concomitant CKD. Because FGF-23
xerts its main biological effects at the renal proximal tubule
9–11), and is tightly linked with kidney dysfunction (12),
e hypothesized that FGF-23 might provide novel insights
nto mechanisms linking CKD with adverse outcomes in
ommunity-living older persons.
ethods
articipants. The CHS (Cardiovascular Health Study) is a
ommunity-based study of older adults that was designed to
valuate risk factors for CVD. The study design and
rotocols have been described previously (13,14). In brief,
ligibility required age 65 years, expectation to remain in
he area for 3 years after recruitment, no active cancer
reatment, and the ability to provide consent. Between 1989
nd 1990, 5,201 participants were recruited from 4 U.S.
ommunities using Medicare eligibility lists. An additional
87 African Americans were recruited in 1992 and 1993.
n-person examinations were performed annually through
998 and 1999 and again in 2005 and 2006. Telephone
nterviews were conducted semiannually from 1989 to 1999
nd biannually thereafter. We conducted FGF-23 measure-
ents at the 1996-97 study visit, selected as it was the first
isit at which urine albumin to creatinine ratio (ACR) was
easured. Among 3,406 individuals who participated, we
xcluded individuals with insufficient blood specimens for
GF-23 measurement (n 69), missing creatinine (n 1),
ystatin C (n  0), urine ACR (n  92), or covariate datan  137) resulting in a final
nalytic sample of 3,107 partici-
ants for this analysis.
easurements. FGF-23. Fasting
8-h) ethylenediamine tetraacetic
cid specimens collected at the
996-97 study visit were stored
t 70°C until 2010, when they
ere thawed and measured for
GF-23 using a C-terminal ELISA
it (Immutopics, San Clemente,
alifornia) (15). Our estimates of
he intra-assay and interassay co-
fficients of variation ranged
rom 7.4% and 10.6%.
OUTCOMES. Methods of ascer-
ainment for, and adjudication
f, death, HF, and CVD events
ave been described previously
16–19). In brief, deaths were identified by review of
bituaries, medical records, death certificates, the Centers
or Medicare and Medicaid Services healthcare-utilization
atabase for hospitalizations, and from household contacts.
he study achieved 100% complete follow-up for ascertain-
ent of mortality status.
All HF and CVD events were adjudicated by the CHS
vents Committee. Participants with history of HF were
xcluded in analyses evaluating incident HF, and likewise,
hose with prevalent CVD (history of myocardial infarction
MI], percutaneous coronary intervention, coronary artery
ypass graft surgery, transient ischemic attack, stroke, or
laudication) were excluded in incident CVD events analy-
es. Incident HF required a physician’s diagnosis of HF, and
djudication by the Events Committee required symptoms,
igns, chest radiographic findings, and treatment of HF
16,17). We evaluated a composite CVD outcome defined
s incident fatal or nonfatal MI, incident fatal or nonfatal
troke, and CVD death, whichever came first. MI was
scertained from hospital records and was indicated by a
linical history of cardiac symptoms, elevated cardiac en-
yme concentrations, and serial electrocardiographic
hanges (17). Cases of possible stroke were adjudicated by a
ommittee of neurologists, neuroradiologists, and internists
n the basis of interviews with patients, medical records,
nd brain imaging studies (18). CVD death was defined as
eath caused by coronary heart disease, HF, peripheral
rterial disease, or cerebrovascular disease (19).
OTHER MEASUREMENTS. Information on baseline con-
founders were obtained at the 1996-97 study visit concurrent
with FGF-23 and included age, sex, race, self-reported health
status and CVD risk factors including hypertension (systolic
blood pressure 140 mm Hg, diastolic blood pressure 90
mm Hg, or use of antihypertensive medications), impaired
fasting glucose (fasting glucose 100 to 125 mg/dl), diabetes
Abbreviations
and Acronyms
ACR  albumin to
creatinine ratio(s)
CI  confidence interval
CKD  chronic kidney
disease
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
FGF  fibroblast growth
factor
HF  heart failure
HR  hazard ratio
IQR  interquartile range
MI  myocardial infarction(fasting glucose 126 mg/dl or use of antiglycemic medica-
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FGF23 and CVD Events in the Community July 17, 2012:200–7tions or insulin), smoking (current, former, or never), body
mass index, total cholesterol, use of lipid lowering medications,
and C-reactive protein concentrations (20).
Cystatin C concentrations were measured using a BN II
nephelometer (Siemens, Munich, Germany) (10). Estimated
glomerular filtration rate (eGFR) was calculated using the
equation: eGFR  76.7  cystatin C (mg/l)1.19 (21). In
ompanion analyses, we calculated eGFR using serum creati-
ine and the CKD-epidemiology equation (22). A random
orning urine sample was obtained and measured for urine
lbumin by rate nephelometry and creatinine using a Kodak
ktachem 700 Analyzer (Kodak, Rochester, New York), and
rine ACR was calculated in microgram/gram.
tatistical analysis. We categorized participants into quar-
iles based on the distribution of FGF-23 in the study sample
nd evaluated the distribution of confounders across FGF-23
ategories. Next, we evaluated the unadjusted correlation of
GFR and ACR with FGF-23 using Spearman correlation
oefficients. Next, we constructed natural piecewise cubic
pline functions with FGF-23 as the dependent variable and
ith prespecified knots placed at the quartiles of the distribu-
ions of eGFR and ACR. The spline function evaluating
GFR as the predictor of FGF-23 was adjusted for age, sex,
ace, and ACR; conversely, the spline of ACR predicting
GF-23 was adjusted for age, sex, race, and eGFR.
Baseline Characteristics by Quartiles of FGF-23Table 1 Baseline Characteristics by Quartile
1
FGF-23 range, RU/ml 51
Number of participants 792
Demographics
Age, yrs 77 5
Female 421 (53)
Black race 180 (23)
Self-reported health fair or poor 137 (17)
Prevalent HF and CVD
History of HF 25 (3)
History of MI 60 (8)
History of stroke 42 (5)
History of claudication 16 (2)
CVD risk factors
Hypertension 457 (58)
Glycemia status
Impaired fasting glucose 38 (5)
Diabetes 81 (10)
Current smoker 42 (5)
Body mass index, kg/m2 26.3 4.3
Total cholesterol, mg/dl 200 37
Lipid lowering medication 72 (9)
C-reactive protein, mg/l 1.83 (0.91–3.89)
Kidney function
eGFR, ml/min/1.73 m2 81 18
Urine ACR, mg/g 6.86 (4.28–14.33)
Values are n, mean  SD, n (%), or median (interquartile range).
ACR  albumin to creatinine ratio; CVD  cardiovascular disease; eGFR 
HF  heart failure; MI  myocardial infarction; RU  relative units.Cox regression was used to evaluate the association of
GF-23 with each outcome. In models evaluating incident
F and CVD, persons with prevalent disease at baseline
ere excluded. The primary analyses evaluated FGF-23
uartiles using the lowest quartile as the reference category.
e also evaluated FGF-23 as a continuous variable after log
ase 2 transformation, interpreted as “per doubling.” For
ach outcome, an initial model was adjusted for age, sex, and
ace. A second model added self-reported health status,
strogen use among women (23), prevalent CVD and HF
where applicable), traditional CVD risk factors, and
-reactive protein levels. A final model added eGFR and
atural log ACR. Next, we stratified patients by eGFR
60 ml/min/1.73 m2 versus greater and tested interac-
ions of FGF-23 by eGFR for each outcome. Similarly,
e tested interactions by urine ACR dichotomized at 30
g/g. In both cases, associations were stronger in persons
ith CKD, so we defined a single variable of CKD
eGFR 60 ml/min/1.73 m2 or ACR 30 mg/g) and
evaluated an FGF-23  CKD interaction term in the final
adjusted model for each outcome. All analyses were also
repeated in a sensitivity analysis using eGFR by the CKD-
epidemiology collaboration equation (22) in place of eGFR
by cystatin C.
Cardiovascular Health StudyFGF-23: The Cardiovascular Health Study
FGF-23 Quartiles
2 3 4
51–70 71–100 100
785 774 756
77 5 78 5 79 5
44 (57) 491 (63) 503 (67)
15 (15) 96 (12) 106 (14)
52 (19) 139 (18) 266 (35)
41 (5) 55 (7) 150 (20)
59 (8) 93 (12) 127 (17)
52 (7) 38 (5) 58 (8)
16 (2) 27 (4) 39 (5)
82 (61) 492 (64) 523 (69)
51 (7) 66 (9) 60 (8)
03 (13) 114 (15) 155 (21)
46 (6) 77 (10) 75 (10)
.7 4.2 27.3 4.6 27.5 5.3
02 38 204 41 203 42
80 (10) 106 (14) 106 (14)
(0.99–4.64) 2.85 (1.28–5.64) 3.12 (1.50–6.79)
4 17 69 16 58 19
4.50–17.51) 8.34 (4.71–18.97) 13.36 (6.01–54.41): Thes of
4
1
1
4
1
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2
2.19
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8.37 (estimated glomerular filtration rate; FGF  fibroblast growth factor;
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July 17, 2012:200–7 FGF23 and CVD Events in the CommunityResults
Among the 3,107 participants, mean age was 78  5 years
and 60% were women. Nine percent had a history of HF
and 29% had a history of CVD at baseline. The mean eGFR
was 71  19 ml/min/1.73 m2, and median urine ACR was
8.8 (interquartile range [IQR]: 4.7 to 20.4) mg/g. The
distribution of FGF-23 was right skewed, with a median 70
(IQR: 53 to 99) relative units (RU)/ml.
Compared with participants in the lowest FGF-23 quar-
tile, those with higher levels were older, more frequently
women and Caucasian, reported poorer health status, and
had more than 2-fold greater prevalence of HF, MI, and
claudication at baseline, whereas the prevalence of prior
stroke was similar across quartiles (Table 1). Individuals
with higher FGF-23 concentrations also had a higher
prevalence of most traditional CVD risk factors, lower
eGFR, and higher ACR.
The unadjusted Spearman correlation of FGF-23 with
eGFR and ACR were –0.42 and 0.20, respectively (p 
0.001 for each). Spline functions demonstrated that the
relationships of eGFR and ACR with FGF-23 were inde-
pendent of one another. The relationship of eGFR with
FGF-23 appeared to increase consistently at eGFR levels
80 ml/min/1.73m2, independent of age, sex, race, or urine
CR (Fig. 1A). Similarly, urine ACR levels greater than 30
g/g were associated with progressively higher FGF-23
evels, independent of age, sex, race, and eGFR (Fig. 1B).
During a median 10.5 (IQR: 5.9 to 11.5) years of follow-up,
,730 participants died, 697 had incident HF, and 797 had
ncident CVD events. There was a graded relationship of
igher FGF-23 levels with higher event rates for each outcome
Table 2). Associations were particularly strong for all-cause
ortality and HF. These associations were modestly attenu-
ted with adjustment for traditional CVD risk factors. Further
djustment for eGFR and urine ACR attenuated each associ-
tion by about one-half. Nonetheless, compared with the
owest FGF-23 quartile, the highest quartile remained associ-
ted with 40% greater death risk and 50% greater HF risk
ompared with the lowest quartile. The association with
ncident CVD was weaker by the point estimate and not
tatistically significant after adjustment for eGFR and ACR.
esults were similar when eGFR was estimated using creati-
ine instead of cystatin C (data not shown).
We observed that the associations of FGF-23 with each
utcome were significantly stronger among individuals with
KD (all p interactions 0.006) (Fig. 2). Among persons
ithout CKD, statistically significant associations were ob-
erved for FGF-23 with all-cause mortality and incident HF,
ut no association was observed for incident CVD events
Table 3). In contrast, among those with CKD, associations
ere particularly strong for death and incident HF and were
eaker for incident CVD events. When evaluating the com-
onents of the composite incident CVD outcome, high
GF-23 had the strongest association with CVD death,ollowed by incident stroke. No association was observed [etween FGF-23 and incident MI irrespective of CKD status
Online Table 1).
We conducted sensitivity analyses where we used the
KD-epidemiology equation rather than cystatin C to
stimate GFR. In all cases, results were similar when results
ere adjusted for and stratified by CKD-epidemiology–
efined eGFR (data not shown). Lastly, because FGF-23
as correlated with CKD severity, we tested whether the
tronger associations within the CKD stratum might reflect
iffering severity of CKD. To investigate this possibility, we
valuated the final model with additional adjustment for
GFR and urine ACR within the CKD strata. Results were
imilar to the stratified analyses presented previously (haz-
rd ratio [HR] per doubling of FGF-23: 1.29 [95% confi-
ence interval (CI): 1.19 to 1.41] for all-cause death, 1.36
eGFR (ml/min/1.73m2)
FG
F-
23
 (R
U/
ml
)
120 100 80 60 40 20
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100
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ACR (mg/g)
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F-
23
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U/
ml
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1 2 3 45 7910 20 30 100 200 400 700
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Figure 1 Relationship of eGFR and Urine ACR With FGF-23 in
Community-Living Individuals
Cubic spline function demonstrating the adjusted cross-sectional association of
(A) estimated glomerular filtration rate (eGFR) estimated by cystatin C and
(B) albumin to creatinine ratio (ACR) with plasma fibroblast growth factor
(FGF)-23 levels. Red lines represent the adjusted point estimates, and
blue lines represent the 95% confidence intervals. The y axis demonstrates the
change in log FGF-23. The spline function for eGFR (A) was adjusted for age, sex,
race, and urine ACR. Spline function for ACR (B) was adjusted for age, sex, race,
and eGFR. The extreme 2.5% of the distribution of eGFR and ACR were excluded
to avoid improbable extrapolations based on extremes of the data.95% confidence interval: 1.18 to 1.57] for incident HF, and
mellitu
a
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FGF23 and CVD Events in the Community July 17, 2012:200–71.15 [95% confidence interval: 0.99 to 1.35] for incident
CVD events).
Discussion
We demonstrate that high FGF-23 levels are associated with
all-cause mortality and incident HF; associations that were
particularly strong among persons with CKD. Comparatively,
the association of FGF-23 with incident CVD events was
more modest, and driven principally through its association
with CVD death. No independent association was observed
between FGF-23 and incident MI irrespective of CKD status.
We believe the findings of stronger associations in CKD are
robust, in part because of the highly significant p values for
interaction. In parallel, a recent study found that high FGF-23
was associated with greater left ventricular mass in a European
cohort, and this association was also stronger in persons with
CKD (24). Yet the mechanisms responsible for stronger
associations in CKD are uncertain. It is possible that the
processes manifested or caused by higher FGF-23 levels will be
particularly harmful in persons with CKD. For example, recent
studies suggest that FGF-23 may cause increases in left
ventricular mass in vitro and in rodent models (2). Higher
FGF-23 may also indicate an elevated dietary phosphorus load,
and thus a greater need to excrete phosphorus into the urine
(25). Alternatively, high FGF-23 may limit conversion of
25-hydroxy vitamin D to the active hormone calcitriol (26).
Higher phosphorus load and calcitriol deficiency may be
particularly harmful in patients with CKD. Recent studies have
identified both higher serum phosphorus and calcitriol defi-
ciency as independent risk factors for CVD events (27–29),
and in some of our prior studies, we have observed that
Association of FGF-23 With Incident HF, CVD, and All-Cause DeathTable 2 Association of FGF-23 With Incident HF, CVD, and All-C
FGF-23 Quart
1 2
FGF-23 range, RU/ml 51 51–70
All-cause mortality
Annual event rate 4.8% (350/792) 5.6% (397/785) 6
Age- sex- race-adjusted 1.00 (ref) 1.18 (1.02–1.36) 1
 CVD risk factors† 1.00 (ref) 0.98 (0.77–1.25) 1
 Kidney function‡ 1.00 (ref) 1.03 (0.89–1.19) 1
Incident HF§
Annual event rate 2.2% (147/767) 2.7% (169/744) 3
Age- sex- race-adjusted 1.00 (ref) 1.28 (1.02–1.60) 1
 CVD risk factors† 1.00 (ref) 1.21 (0.97–1.51) 1
 Kidney function‡ 1.00 (ref) 1.10 (0.88–1.38) 1
Incident CVD
Annual event rate 3.7% (188/600) 4.5% (213/587) 4
Age- sex- race-adjusted 1.00 (ref) 1.23 (1.01–1.50) 1
 CVD risk factors† 1.00 (ref) 1.17 (0.96–1.43) 1
 Kidney function‡ 1.00 (ref) 1.14 (0.93–1.39) 1
Values are n, % (n events/n at risk), or HR (95% CI). *The p value for the linear Cox model. †Adjus
HF, prior claudication, hypertension, diabetes (NL, IFG, DM), BMI, estrogen use (women), total cho
natural log (ACR). §Excludes 271 participants with prevalent HF at baseline. Excludes 901 partic
BMI  body mass index; CI  confidence interval; CRP  C-reactive protein; DM  diabetes
bbreviations as in Table 1.hyperphosphatemia and vitamin D deficiency are morestrongly associated with subclinical CVD in individuals with
CKD than in those without (30,31).
Another possibility is that high FGF-23 may reflect a
component of kidney dysfunction that is not captured by the
standard clinical markers of eGFR and urine ACR: renal
endocrine resistance to FGF-23 action. Whereas eGFR and
ACR reflect different aspects of kidney function, neither is
a marker of renal endocrine responsiveness. ACR and
eGFR are both strongly and independently associated with
CVD events (11,32) and measuring both in combination
has improved the ability to identify risk of death and CKD
progression (33,34). Here, we demonstrated that despite the
correlation of FGF-23 with both markers, it provided
unique risk information about death, HF, and CVD events.
Moreover, the relative strengths of association of FGF-23
with each outcome have striking similarities to our prior work
evaluating eGFR by cystatin C and creatinine in community-
living cohorts. Elevated concentrations of these markers are
consistently more strongly associated with death and inci-
dent HF than with MI. For example, in CHS, we previ-
ously showed that the highest quintile of cystatin C was
associated with a more than doubling in risk for all-cause
mortality and incident HF, compared with only a 30%
higher relative risk for MI (9,10,35). These findings have
proven consistent in many other studies and settings (36–40).
Much less is known about the comparative strength of
associations of FGF-23 with these outcomes. However, in a
prior study evaluating FGF-23 in a cohort with prevalent
CVD and with a spectrum of kidney function similar to
individuals evaluated here, we also observed that high
FGF-23 was more strongly associated with all-cause mor-
Cardiovascular Health StudyDeath: The Cardiovascular Health Study
Linear Model
3 4 Per Doubling of FGF-23 p Value*
100 100
19/774) 10.3% (554/756)
.12–1.48) 2.29 (2.00–2.62) 1.65 (1.53–1.77) 0.001
.92–1.47) 1.87 (1.49–2.36) 1.49 (1.31–1.69) 0.001
.90–1.21) 1.42 (1.22–1.65) 1.25 (1.14–1.36) 0.001
72/719) 5.3% (209/606)
.10–1.71) 2.47 (1.99–3.07) 1.76 (1.57–1.97) 0.001
.01–1.59) 2.07 (1.66–2.58) 1.62 (1.44–1.83) 0.001
.88–1.39) 1.55 (1.22–1.97) 1.41 (1.23–1.61) 0.001
05/558) 6.5% (191/461)
.07–1.60) 1.74 (1.42–2.14) 1.36 (1.20–1.53) 0.001
99–1.48) 1.50 (1.22–1.86) 1.24 (1.10–1.41) 0.001
92–1.40) 1.30 (1.04–1.63) 1.12 (0.98–1.29) 0.100
age, sex, race, health status (fair or poor vs. better), current smoking, prior stroke, prior MI, prior
, lipid medication use, natural log (CRP). ‡Adjusted for CVD risk factor model (“”) and eGFR and
with prevalent CVD at baseline.
s; HR  hazard ratio; IFG  impaired fasting glucose; NL  normal level; ref  reference; other: Theause
iles
71–
.2% (4
.29 (1
.16 (0
.05 (0
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July 17, 2012:200–7 FGF23 and CVD Events in the Community1.54, 1.31, and 1.05, respectively) (6). The consistency of
these findings and the similar pattern to that observed for
eGFR lead us to propose the novel hypothesis that high
FGF-23 may be marking a novel axis of kidney dysfunction,
and that its measurement may provide information about
other dimensions of kidney function beyond that obtained
by measurement of eGFR and ACR.
The 2 pathways hypothesized herein linking FGF-23 with
adverse outcomes are not mutually exclusive. At any level of
eGFR and ACR, a higher FGF-23 may indicate impaired
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Figure 2
Associations of FGF-23 Quartiles and Risk of
All-Cause Mortality, Incident HF, and Incident
CVD Events: The Cardiovascular Health Study
Annual event rates of (A) all-cause mortality, (B) incident heart failure (HF),
and (C) incident cardiovascular disease (CVD) events by quartiles of fibroblast
growth factor (FGF)-23, stratified by chronic kidney disease (CKD) status.
Patients with prevalent HF and CVD at the baseline examination were excluded
from B and C, respectively.renal endocrine resistance. At the same time, higher FGF-23 emay directly lead to adverse cardiovascular consequences by
mechanisms of calcitriol deficiency, altered phosphorus ho-
meostasis, or direct effects on cardiac myocytes (2,41,42). The
mechanisms linking CKD to HF, CVD, and death have
remained elusive despite intensive research (43) and wide-
spread recognition of the importance of this relationship to
public health (44). The strength of association of FGF-23 with
these outcomes in individuals with CKD reported here and
elsewhere (3,6) suggests that further research focused on
FGF-23 mechanisms may provide important insights into
CVD risk among persons with CKD.
To our knowledge, only 1 prior study has examined the
association of FGF-23 with CVD in community-living
individuals not selected based on pre-existing CKD or
CVD. In the HPFS (Health Professionals Follow-up
Study), Taylor et al. (8) reported no statistically significant
association of FGF-23 with the composite outcome of
nonfatal MI and fatal coronary heart disease. These findings
are consistent with our own. In combined analysis among
persons with and without CKD, we observed strong asso-
ciations of FGF-23 with death and HF, but we observed
null findings with CVD events. Moreover, in the HPFS,
among the 422 coronary heart disease cases, 333 (79%) were
nonfatal MI events, and in our study the association of
FGF-23 with MI was particularly modest. Participants in
HPFS had significantly higher eGFR at baseline compared
with those in the CHS. The HPFS investigators reported
that results were similar when restricting to persons with
eGFR 60 ml/min/1.73 m2. However, they did not report
interactions by CKD, nor did they show associations sepa-
rately in those with eGFR 60 ml/min/1.73 m2, perhaps
ecause power was too low to do so within the CKD strata.
he HPFS did not evaluate associations with HF or
ll-cause death. Thus, the present study considerably ex-
ends the findings of FGF-23 in the general population by
valuating long-term follow-up and considerably greater
umber of events; provides the first comparison of strengths
f association between death, HF, and CVD in the general
opulation; and examines associations separately in those
ith and without CKD.
tudy strengths. Strengths of our study include the exter-
al validity of a large community-based population, long
uration and complete follow-up, large number of events,
djudication of HF and CVD events by a panel of experts,
nd availability of cystatin C and urine ACR measurements
oncurrent with FGF-23.
tudy limitations. Sophisticated measures of subclinical
VD and other measures of mineral metabolism comple-
entary to FGF-23 (serum phosphorus, calcitriol, and
lotho) were not available to provide additional insights to
nderlying mechanisms. All participants were recruited in
.S. cities and were older and of black or white race. Results
ay differ in other settings. Results are observational in
ature, so residual confounding may persist and causal
ffects of FGF-23 cannot be determined.
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FGF23 and CVD Events in the Community July 17, 2012:200–7Conclusions
In community-living older persons, very modest decrements
in eGFR and elevations in urine ACR are each indepen-
dently associated with higher FGF-23. High FGF-23, in
turn, is associated with all-cause mortality and incident HF;
associations that are particularly strong in persons with
CKD. The association of FGF-23 with incident CVD
events was modest in comparison. Measurement of FGF-23
may provide new insights to kidney function beyond eGFR
and ACR and to the elusive mechanisms linking CKD to
CVD events.
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Association of FGF-23 With Incident HF, CVD, and All-Cause DeathTable 3 Association of FGF-23 With Incident HF, CVD, and All-C
FGF-23 Quartile
1 2
FGF-23 range, RU/ml 51 51–70
CKD (n  1,128)
All-cause mortality
Annual event rate 7.7 (90/141) 7.6 (150/235) 8.7
Adjusted hazard
ratio†
1.00 (ref) 0.97 (0.75–1.26) 1.09
Incident HF‡
Annual event rate 3.7 (38/136) 3.8 (63/213) 4.6
Adjusted hazard
ratio†
1.00 (ref) 0.97 (0.64–1.46) 1.16
Incident CVD§
Annual event rate 5.1 (39/104) 6.2 (71/156) 6.2
Adjusted hazard
ratio†
1.00 (ref) 1.09 (0.74–1.63) 1.09
No CKD (n  1,979)
All-cause mortality
Annual event rate 4.3 (270/651) 4.8 (247/550) 5.0
Adjusted hazard
ratio†
1.00 (ref) 1.10 (0.93–1.32) 1.15
Incident HF‡
Annual event rate 1.9 (109/631) 2.3 (106/531) 2.3
Adjusted hazard
ratio†
1.00 (ref) 1.19 (0.90–1.56) 1.11
Incident CVD§
Annual event rate 3.5 (149/496) 4.0 (142/431) 4.2
Adjusted hazard
ratio†
1.00 (ref) 1.12 (0.89–1.42) 1.16
Values are n, % (n events/n at risk), or HR (95% CI). CKD defined as either eGFR 60 ml/min/1.7
status (fair or poor vs. better), current smoking, prior stroke, prior MI, prior HF, prior claudication,
natural log (CRP). The p values for interaction in the adjusted model were0.001 for all-cause mo
failure at baseline. §Excludes 901 participants with prevalent CVD at baseline.
CKD  chronic kidney disease; other abbreviations as in Tables 1 and 2.ucsd.edu.REFERENCES
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APPENDIX
For a table showing the associations of FGF-23 with components of
incident CVD event outcome stratified by CKD as found in the CHS,
please see the online version of this article.
